This study compares a new biosimilar drug (GME751) to the standard immunotherapy Keytruda in 322 adults with stage II or III melanoma that has been completely removed by surgery. The goal is to see if the biosimilar is absorbed and works similarly in the body. Participants receiv…
Phase: PHASE1 • Sponsor: Sandoz • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC